申请人:MEDIVIR AB
公开号:WO2009053277A1
公开(公告)日:2009-04-30
The invention provides compounds of the formula (I) wherein A is selected from the partial structures A1, A2 and A3; Ry and Ry' are both hydrogen, or Ry and Ry' together with the nitrogen atom to which they are attached form a cyclic amine such as morpholine, piperidine, piperazine or pyrrolidine; L is NHNH, CH2NH, O or S; Y is NH, NHNH, NHC(=O), S(=O)2NH, NHS(=O)2, CH2, CH2NH, O, S or S(=0)p; Q is aryl or heterocyclyl; Z is O, S, NRa or S(=0)p; m is O, 1 or 2; n is O, 1, 2 or 3; p is independently 1 or 2; q is 0 or 1; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C3-C7cycloalkylC0-C3alkyl, arylC0-C3alkyl or heterocyclylC0-C3alkyl, R4'' is H or C1-C6alkyl; or R4' and R4'' together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is H, C1-C6alkyl, C3-C7ycycloalkyl, aryl or heterocyclyl; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.
该发明提供了以下式(I)的化合物,其中A从部分结构A1、A2和A3中选择;Ry和Ry'都是氢,或者Ry和Ry'与它们连接的氮原子一起形成环状胺,如吗啉、哌啶、哌嗪或吡咯烷;L为NHNH、CH2NH、O或S;Y为NH、NHNH、NHC(=O)、S(=O)2NH、NHS(=O)2、CH2、CH2NH、O、S或S(=0)p;Q为芳基或杂环烷基;Z为O、S、NRa或S(=0)p;m为O、1或2;n为O、1、2或3;p独立地为1或2;q为0或1;Ra为H或C1-C4烷基;R1为氢、C1-C6烷基、C3-C7环烷基C0-C3烷基、芳基C0-C3烷基或杂环烷基C0-C3烷基,R4''为H或C1-C6烷基;或R4'和R4''与它们连接的碳原子一起定义为C3-C6环烷基;W为H、C1-C6烷基、C3-C7环烷基、芳基或杂环烷基;或其药学上可接受的盐、水合物或N-氧化物。该发明的化合物是天冬氨酸蛋白酶的抑制剂,如肾素,用于治疗与RAS活动相关的疾病,如高血压、心力衰竭和肾功能不全等。